Harmony Biosciences Holdings, Inc.
NASDAQ:HRMYBiotechnology
-$0.61 today
- Market cap
- $1.94B
- Beta
- 0.97
- P/E (TTM)
- 13.2
- EPS (TTM)
- $2.52
Volume 0.57M
Average 0.82M
HRMY Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Harmony Biosciences Holdings, Inc.NASDAQ: HRMY
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities rises 495.8% from a year ago
Other current liabilities stood at $13.17M at the end of Q2 FY2026, up 495.8% from a year earlier and down 88.9% from the prior quarter. Over 3 fiscal years it compounded at +330.0% a year.
Context
- Other current liabilities amounted to 1.0% of total assets at the end of Q2 FY2026, up 0.8 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +495.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 129.1M USD
- Year-over-year change
- +2865.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 129.1M | +2865.2% |
| FY2024 | 2024-12-31 | 4.35M | -95.9% |
| FY2023 | 2023-12-31 | 107.3M | +6507.4% |
| FY2022 | 2022-12-31 | 1.62M | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Liabilities vs competitors
How HRMY compares with its peers on the latest reported figures
- HRMY's Jun 2026 other current liabilities of $13.17M is the 3rd highest of the 4 companies compared; the peer median is $140.87M.
- Its year-over-year change of +495.8% is the lowest of 2, against a peer median of +450133.7%.
- Other current liabilities amounts to 1.0% of total assets for HRMY, versus a peer median of 4.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.96B | +450133.7% | — | 4.2% | |
| Mar 2026 | $140.87M | — | +225.2% | 26.5% | |
| Jun 2026 | $13.17M | +495.8% | +330.0% | 1.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $1.97M | — | +136.0% | 0.5% |
APMDApnimed, Inc. | — | — | — | — | — |
| Peer median (excluding HRMY) | $140.87M | +450133.7% | +180.6% | 4.2% | |
Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 234.31M | 243.78M | 311.66M | 453M | 752.5M |
| Short-term Investments | 0 | 79.33M | 41.8M | 14.19M | 22.84M |
| Net Receivables | 34.84M | 54.74M | 74.14M | 83.03M | 96.79M |
| Inventory | 4.43M | 4.3M | 5.36M | 7.2M | 5.36M |
| Other Current Assets | 3.22M | 8.79M | 5.54M | 8.12M | 13.52M |
| Total Current Assets | 284.44M | 400.29M | 451.07M | 579.25M | 907.01M |
| Property, Plant & Equipment (Net) | 4.12M | 573K | 371K | 3.38M | 5.34M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 143.92M | 160.95M | 137.11M | 113.26M | 89.42M |
| Long-term Investments | 0 | 22.57M | 72.17M | 108.87M | 107.4M |
| Tax Assets | 0 | 85.94M | 144.16M | 0 | 149.7M |
| Other Non-current Assets | 967K | 3.55M | 6.57M | 194.43M | 12.76M |
| Total Non-current Assets | 149M | 273.59M | 360.38M | 419.95M | 364.62M |
| Total Assets | 433.44M | 673.87M | 811.45M | 999.2M | 1.27B |
| Account Payables | 1M | 3.79M | 17.73M | 13.74M | 17.69M |
| Short-term Debt | 2M | 2M | 15M | 16.25M | 86.89M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 1.62M | 107.3M | 4.35M | 129.1M |
| Total Current Liabilities | 53.78M | 78.88M | 163.78M | 175.08M | 252.13M |
| Long-term Debt | 189.98M | 189.65M | 178.57M | 163.02M | 148.18M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 777K | 2.5M | 2.11M | 1.13M | (3.41M) |
| Total Non-current Liabilities | 193.16M | 192.15M | 180.68M | 164.96M | 149.28M |
| Total Liabilities | 246.94M | 271.03M | 344.46M | 340.05M | 401.41M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | (453.6M) | (272.13M) | (143.28M) | 2.22M | 160.9M |
| Accumulated OCI | 0 | (151K) | 2K | 66K | 346K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 186.51M | 402.84M | 466.99M | 659.16M | 870.22M |
| Total Debt | 195.74M | 191.65M | 193.57M | 181.41M | 239.58M |
| Net Debt | (38.57M) | (52.14M) | (118.09M) | (271.6M) | (512.92M) |
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
Intrinsic Alpha fair value
Locked
Current Price
$33.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.